12 September 2023 - Ferring launches ABLE-41 Real World Evidence Study, a patient registry to explore early use, experiences and outcomes of Adstiladrin in a real world setting.

Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer was dosed with the commercially available intravesical gene therapy Adstiladrin (nadofaragene firadenovec-vncg) as part of the Adstiladrin Early Experience Program announced earlier this year.

Read Ferring Pharmaceuticals press release